Safety and Immunogenicity of a Vero-cell-Derived, Inactivated Japanese Encephalitis Vaccine: A Non-inferiority, Phase III, Randomised Controlled Trial

Published in The Lancet, this study demonstrates a strong immunogenicity and safety profile among adults for a JE vaccine under development by Intercell. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Tauber E, Kollaritsch H, Korinek M, et al.

Published: 2007

  • Visit web page (English)

    (Located at www.thelancet.com)

    Citation: Tauber E, Kollaritsch H, Korinek M, et al. Safety and Immunogenicity of a Vero-cell-derived, Inactivated Japanese Encephalitis Vaccine: A Non-inferiority, Phase III, Randomised Controlled Trial. The Lancet. 2007;370(9602):1847-1853.